190 results on '"Winkelmann, Michael"'
Search Results
2. Patient eligibility for trials with imaging response assessment at the time of molecular tumor board presentation
3. Multicenter development of a PET-based risk assessment tool for product-specific outcome prediction in large B-cell lymphoma patients undergoing CAR T-cell therapy
4. Reliability and practicability of PSMA-RADS 1.0 for structured reporting of PSMA-PET/CT scans in prostate cancer patients
5. Predictive value of pre-infusion tumor growth rate for the occurrence and severity of CRS and ICANS in lymphoma under CAR T-cell therapy
6. Lenticulostriatal Ischemia Shows Relevant SSTR Expression on PET/CT Imaging Using the Novel SSTR-Targeting Peptide 18F-SiTATE
7. Quantitative SSTR-PET/CT: a potential tool for predicting everolimus response in neuroendoctine tumour patients
8. Utility of clinical and MR imaging parameters for prediction and monitoring of response to capecitabine and temozolomide (CAPTEM) therapy in patients with liver metastases of neuroendocrine tumors
9. Quantitative SSTR-PET/CT for predicting response and survival outcomes in patients with pancreatic neuroendocrine tumors receiving CAPTEM
10. Next-generation PET/CT imaging in meningioma—first clinical experiences using the novel SSTR-targeting peptide [18F]SiTATE
11. Neuroendocrine liver metastases treated using transarterial radioembolization: Identification of prognostic parameters at 68Ga-DOTATATE PET/CT
12. Validation of the SSTR-RADS 1.0 for the structured interpretation of SSTR-PET/CT and treatment planning in neuroendocrine tumor (NET) patients
13. Prognostic value of the International Metabolic Prognostic Index for lymphoma patients receiving chimeric antigen receptor T-cell therapy
14. Staging of lymphoma under chimeric antigen receptor T-cell therapy: reasons for discordance among imaging response criteria
15. Metabolic patterns on [18F]FDG PET/CT in patients with unresectable stage III NSCLC undergoing chemoradiotherapy ± durvalumab maintenance treatment
16. Prognostic value of pre-infusion tumor growth rate for patients with lymphoma receiving chimeric antigen receptor T-cell therapy
17. Correction to: Next‑generation PET/CT imaging in meningioma—first clinical experiences using the novel SSTR‑targeting peptide [18F]SiTATE
18. Liver-FDG-uptake and CAR T-cell kinetics augment early PET/CT prognostic value for CD19-targeted CAR T-cell therapy in diffuse large B cell lymphoma
19. Multicenter development of a PET-based risk assessment tool for product-specific outcome prediction in large B-cell lymphoma patients undergoing CAR T-cell therapy
20. Early quantification of anti-CD19 CAR T cells by flow cytometry predicts response in R/R DLBCL
21. Functional connectivity MRI provides an imaging correlate for CAR T cell associated neurotoxicity
22. Modification of Lugano criteria by pre-infusion tumor kinetics improves early survival prediction for patients with lymphoma under chimeric antigen receptor T-cell therapy
23. Evaluation of MRI in the diagnostic accuracy of extrahepatic metastases in neuroendocrine tumors in comparison with the reference standard somatostatin-receptor–PET/CT
24. PET/CT imaging for tumour response assessment to immunotherapy: current status and future directions
25. Transformation of diffuse large B cell lymphoma into dendritic sarcoma under CAR T cell therapy detected on 18F-FDG PET/CT
26. Supplementary Figures from Influence of Adipose Tissue Distribution, Sarcopenia, and Nutritional Status on Clinical Outcomes After CD19 CAR T-cell Therapy
27. Supplementary Tables from Influence of Adipose Tissue Distribution, Sarcopenia, and Nutritional Status on Clinical Outcomes After CD19 CAR T-cell Therapy
28. Data from Influence of Adipose Tissue Distribution, Sarcopenia, and Nutritional Status on Clinical Outcomes After CD19 CAR T-cell Therapy
29. Influence of Adipose Tissue Distribution, Sarcopenia, and Nutritional Status on Clinical Outcomes After CD19 CAR T-cell Therapy
30. MP09-14 RADIOMIC ANALYSIS TO DISTINGUISH BETWEEN UPPER TRACT UROTHELIAL CARCINOMA AND RENAL CELL CARCINOMA: CAN WE IMPROVE IMAGING USING MACHINE LEARNING?
31. Additional file 1 of Patterns of pseudoprogression across different cancer entities treated with immune checkpoint inhibitors
32. Additional file 3 of Patterns of pseudoprogression across different cancer entities treated with immune checkpoint inhibitors
33. Additional file 4 of Patterns of pseudoprogression across different cancer entities treated with immune checkpoint inhibitors
34. Additional file 7 of Patterns of pseudoprogression across different cancer entities treated with immune checkpoint inhibitors
35. Additional file 9 of Patterns of pseudoprogression across different cancer entities treated with immune checkpoint inhibitors
36. Additional file 6 of Patterns of pseudoprogression across different cancer entities treated with immune checkpoint inhibitors
37. Additional file 5 of Patterns of pseudoprogression across different cancer entities treated with immune checkpoint inhibitors
38. Additional file 2 of Patterns of pseudoprogression across different cancer entities treated with immune checkpoint inhibitors
39. Lenticulostriatal Ischemia Shows Relevant SSTR Expression on PET/CT Imaging Using the Novel SSTR-Targeting Peptide 18F-SiTATE.
40. Prognostic value of the International Metabolic Prognostic Index for lymphoma patients receiving chimeric antigen receptor T-cell therapy
41. Density of the Spleen in Low-Dose CT Scans Is Associated with High-Risk Disease Features and Shorter Survival in Newly Diagnosed Multiple Myeloma Patients
42. Early Real Time Quantification of CD19. CAR T Cells By Flow Cytometry As a Predictive Biomarker for Response in Patients with R/R LBCL
43. Body Composition and Immunonutritional Status Impact Survival Outcomes after CD19 CAR T-Cell Therapy
44. Treatment Assessment of pNET and NELM after Everolimus by Quantitative MRI Parameters
45. The cytokine midkine supports neutrophil trafficking during acute inflammation by promoting adhesion via β2 integrins (CD11/CD18)
46. Next-generation PET/CT imaging in meningioma—first clinical experiences using the novel SSTR-targeting peptide [18F]SiTATE.
47. Metabolic patterns on [18F]FDG PET/CT in patients with unresectable stage III NSCLC undergoing chemoradiotherapy ± durvalumab maintenance treatment.
48. Chimeric Antigen Receptor T-cell Therapy: Imaging Response Criteria and Relation to Progression-free and Overall Survival
49. Lymphoma tumor burden before chimeric antigen receptor T-Cell treatment: RECIL vs. Lugano vs. metabolic tumor assessment
50. Patterns of pseudoprogression across different cancer entities treated with immune checkpoint inhibitors.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.